Technology ID
TAB-4840

Development and Testing of a Novel CMV-Based Vaccine Prototype

E-Numbers
E-020-2018-0
Lead Inventor
Jarvis, Michael
Lead IC
NIAID
Co-Inventors
Murphy, Aisling
Powers, Ilhem
Feldmann, Heinrich (Heinz)
Marzi, Andrea
ICs
NIAID
Applications
Vaccines­­­
Therapeutic Areas
Infectious Disease
Development Stages
Pre-clinical (in vivo)
Research Products
Plasmids/Vectors
Animal Models

The collaborative effort between the Jarvis Laboratory at the University of Plymouth and Feldmann's laboratory led to the development and testing of a groundbreaking Cytomegalovirus (CMV)-based vaccine designed to express the Ebola virus glycoprotein. This innovative approach aimed to enhance Ebola virus-specific immunogenicity and efficacy. The Jarvis Laboratory was responsible for the initial design and construction of the vaccine prototype, while Feldmann's team conducted extensive testing for immunogenicity and efficacy using a nonhuman primate model. The successful outcomes of these studies, documented in the 2016 publication by Marzi et al., represent a significant advancement in Ebola virus vaccine research, demonstrating the potential of CMV-based vaccines in combating infectious diseases.

Commercial Applications
The CMV-based Ebola vaccine has significant potential for controlling and preventing Ebola outbreaks due to its enhanced immunity. Its successful testing in nonhuman primate models indicates strong prospects for human application, especially in Ebola-prone areas. Furthermore, the innovative use of the CMV vector could revolutionize vaccine development for other challenging infectious diseases, contributing substantially to global pandemic preparedness and health security.

Competitive Advantages
The CMV-based Ebola vaccine, collaboratively developed by the Jarvis and Feldmann laboratories, stands out for its use of the CMV vector, known for inducing strong, lasting immune responses. This innovative approach potentially offers greater efficacy and durability than traditional vaccines. Successfully tested in a nonhuman primate model, it demonstrates significant promise for human efficacy, particularly with its targeted response against the Ebola glycoprotein. The combined expertise of both labs in design and testing further enhances its competitive edge in the vaccine research field.
Licensing Contact:
Joyce, Terrence
terrence.joyce@nih.gov